Bayer grows Asian diabetes care business:
This article was originally published in Clinica
Executive Summary
Bayer HealthCare is adding two new blood glucose management systems, Breeze and Brio, to its offerings in China and Korea in a bid to capitalise on the growing, and yet underpenetrated, diabetes care market in Asia. The company (part of the German drugs giant Bayer) will also be conducting information campaigns in both countries to educate people about the value of better diabetes management through regular blood glucose monitoring, diet, exercise and medication. The number of new diabetes cases in Asia is expected to more than double by 2025, according to the International Diabetes Federation. Of the 40 million in China suffering from the disorder, only 2% own a blood glucose meter for regular monitoring of their blood glucose level.